Analysts’ recommendations on Stryker
Stryker (SYK) announced its 3Q17 earnings results on October 26, 2017. In this article, we’ll look at analysts’ ratings, recommendations, and target prices for Stryker over the next 12 months. As of October 30, 2017, of 28 investment research companies surveyed by Reuters, 17 (61%) recommended “buy” for Stryker, nine recommended “hold,” and two recommended “sell.”
The table above summarizes recommendations for Stryker over the next year. Analysts’ 12-month target price for SYK stock is $157.50, which represents a potential return of approximately -1.4% based on the stock’s closing price of $159.70 on October 29, 2017.
Peers Zimmer Biomet (ZBH), Medtronic (MDT), and Thermo Fisher Scientific (TMO) have target prices of $135.10, $89.90, and $219.10, respectively, for the next 12 months. These target prices represent 12-month returns of 11.3%, 11.7%, and 14.1%, respectively.
Analysts’ recommendation revisions
After the company released its 3Q17 earnings results on October 26, 2017, some brokerages updated their ratings and recommendations on SYK stock. On October 27, 2017, Canaccord Genuity maintained its “buy” rating on Stryker, and increased its target price for the stock from $155 to $162. Piper Jaffray released a report on October 27, 2017, reiterating its “buy” rating on SYK stock. It has a target price of $156 for the stock. Barclays kept its “underweight” rating on the stock, with a target price of $148, even after the company’s strong performance. For exposure to Stryker, investors could consider the Vanguard Dividend Appreciation ETF (VIG), of which SYK makes up ~1.6%.